Investigational drug · Phase 3
Tiragolumab
Also called: MTIG7192A, RO7092284
Not approved by FDA. In 11 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hepatocellular Carcinoma, Rectal Neoplasms, Rectal Cancer.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
11
5 still active
All registered trials
67
Any phase or sponsor naming "Tiragolumab"
First trial start
2017
Jul 5, 2017
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Tiragolumab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hepatocellular Carcinoma
- Rectal Neoplasms
- Rectal Cancer
- Advanced Liver Cancers
- Urothelial Cancer
- Cancer
- PD-L1-selected Solid Tumors
- Pancreatic Adenocarcinoma
- Non-small Cell Lung Cancer (NSCLC)
- Esophageal Squamous Cell Carcinoma
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Pancreatic cancer · Liver cancer (hepatocellular carcinoma) · Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Tiragolumab" as an intervention, largest first.
- A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)Pivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04513925 · 829 participants · Start Aug 24, 2020 · Primary completion May 27, 2025
Drug: Atezolizumab; Tiragolumab and 1 more · For: Non-small Cell Lung Cancer (NSCLC)
Sites: Palo Alto, California; Greeley, Colorado; Fort Myers, Florida · 189 sites in all
- A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent ChemoradiotherapyPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04543617 · 760 participants · Start Sep 28, 2020 · Primary completion Jul 22, 2026
Drug: Tiragolumab; Atezolizumab and 2 more · For: Esophageal Squamous Cell Carcinoma
Sites: Fort Myers, Florida; Wichita, Kansas; Williamsville, New York · 166 sites in all
- A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)Pivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05904886 · 687 participants · Start Sep 14, 2023 · Primary completion May 8, 2025
Drug: Atezolizumab; Bevacizumab and 1 more · For: Hepatocellular Carcinoma
Sites: Hot Springs, Arkansas; Clovis, California; Duarte, California · 171 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04294810 · 620 participants · Start Mar 4, 2020 · Primary completion Dec 30, 2025
Drug: Atezolizumab; Tiragolumab and 1 more · For: Non-Small Cell Lung Cancer
Sites: Denver, Colorado; New Haven, Connecticut; St. Petersburg, Florida · 132 sites in all
- A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)Pivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04929223 · 542 participants (planned) · Start Oct 22, 2021 · Primary completion Aug 31, 2030
Drug: Inavolisib; Bevacizumab and 7 more · For: Metastatic Colorectal Cancer
Sites: Birmingham, Alabama; Phoenix, Arizona; Duarte, California · 84 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04619797 · 542 participants · Start Dec 15, 2020 · Primary completion Apr 19, 2024
Drug: Tiragolumab; Atezolizumab and 5 more · For: Non-small Cell Lung Cancer (NSCLC)
Sites: Los Angeles, California; Whittier, California; Fort Myers, Florida · 127 sites in all
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT02794571 · 518 participants · Start May 23, 2016 · Primary completion Nov 13, 2024
Drug: Atezolizumab; Tiragolumab and 8 more · For: Advanced/Metastatic Tumors
Sites: Scottsdale, Arizona; Santa Monica, California; New Haven, Connecticut · 28 sites in all
- A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)Pivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04524871 · 518 participants (planned) · Start Nov 1, 2020 · Primary completion Jul 30, 2027
Drug: Atezolizumab; Bevacizumab 15 mg/kg and 11 more · For: Advanced Liver Cancers
Sites: Costa Mesa, California; Duarte, California; Orange, California · 32 sites in all
- A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung CancerPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04256421 · 490 participants · Start Feb 4, 2020 · Primary completion Sep 6, 2022
Drug: Tiragolumab; Atezolizumab and 3 more · For: Small Cell Lung Cancer
Sites: Lone Tree, Colorado; Washington D.C., District of Columbia; Fort Myers, Florida · 121 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04540211 · 461 participants · Start Oct 30, 2020 · Primary completion Feb 13, 2023
Drug: Atezolizumab; Tiragolumab and 4 more · For: Esophageal Cancer
Sites: Anhui, China; Anyang, China; Beijing, China · 67 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Old disease, new twist.
Roudsari H, Dhaliwal G, Jagannath AD, et al. · J Hosp Med 2026
- Atezolizumab with or without tiragolumab in unresectable esophageal squamous-cell carcinoma following definitive concurrent chemoradiotherapy (SKYSCRAPER-07): a randomised, phase III study.
Xu RH, Cho BC, Chen M, et al. · Ann Oncol 2026
- SKYSCRAPER-03: a phase III study of tiragolumab plus atezolizumab versus durvalumab in locally advanced, unresectable, stage III NSCLC after platinum-based concurrent chemoradiation.
Wakelee HA, Ahn MJ, Bradley J, et al. · Ann Oncol 2026
- A randomised, open-label, phase II study of tobemstomig combinations in patients with previously untreated advanced clear-cell renal cell carcinoma.
Rini BI, Powles T, Tomczak P, et al. · ESMO Open 2026
- SKYSCRAPER-05: A Phase 2 Study of Perioperative Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Patients With Previously Untreated, Locally Advanced, Resectable, Stage IIߜIIIB NSCLC.
Shu CA, Kim AW, Hong MH, et al. · JTO Clin Res Rep 2026
- Investigation of excipient-related artifacts observed in the leachables study of tiragolumab by LC-HRMS and GC-MS.
Du J, Pearson R, Zhou Y, et al. · J Pharm Biomed Anal 2026
Also in development for Hepatocellular Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- CadonilimabAK104Phase 331 trials
Akeso · Hepatocellular Carcinoma, Gastric / Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- PF-08634404SSGJ-707Phase 312 trials
Pfizer · Non-Small Cell Lung Cancer, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung (NSCLC)
- FianlimabREGN3767Phase 311 trials
Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- ZG005Phase 311 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.